Revolax Fine — Monophasic HA Filler for Superficial Lines (1 x 1.1ml)

Revolax Fine is Across Co.’s lightest variant — 20 mg/mL cross-linked HA + 0.3% lidocaine in a uniform monophasic structure produced via BDDE cross-linking. Engineered for superficial dermal placement targeting fine worry lines, crow’s feet, glabella creases, and neck wrinkles. The monophasic structure ensures even gel distribution without free HA.

Revolax Fine with Lidocaine is manufactured by Across Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2009. The product is part of the Revolax dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · CE marked · GMP certified.

Revolax Fine with Lidocaine contains 20 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Across Co. Ltd.’s Dense Monophasic BDDE Cross-Linking technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Across Co. Ltd.’s clinical data, Revolax Fine with Lidocaine delivers 8-12 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Superficial dermis placement typically delivers the longer end of the duration range.

Revolax Fine with Lidocaine is engineered for superficial dermis placement. The standard recommended needle is 30G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Revolax Fine with Lidocaine regulatory status: KFDA registered · CE marked · GMP certified. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Revolax Fine with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Revolax Fine with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Revolax Fine with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Monophasic means Revolax Fine is produced as a single, uniform gel phase rather than a mixture of cross-linked particles in HA fluid (which is biphasic). The monophasic structure ensures even gel distribution during injection without ‘free’ (non-cross-linked) HA — supporting smoother extrusion, more predictable placement, and reduced lump risk. Revolax’s monophasic gel uses BDDE cross-linking with dense, regular lattice structure — making it stable, consistent in viscosity, and resistant to migration in the placement zone.